Korean Journal of Clinical Oncology (대한종양외과학회지)

Korean Society of Surgical Oncology (대한종양외과학회)
권호 표지
DOI QR코드

DOI QR Code

Long-term cardiac composite risk following adjuvant treatment in breast cancer patients

  • Choi, Hong Bae (Department of Surgery, Soonchunhyang University Seoul Hospital) ;
  • Yun, Sangchul (Department of Surgery, Soonchunhyang University Seoul Hospital) ;
  • Cho, Sung Woo (Department of Surgery, Soonchunhyang University Seoul Hospital) ;
  • Lee, Min Hyuk (Department of Surgery, Soonchunhyang University Seoul Hospital) ;
  • Lee, Jihyoun (Department of Surgery, Soonchunhyang University Seoul Hospital) ;
  • Park, Suyeon (Department of Biostatistics, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medical Sciences)
  • Received : 2018.06.19
  • Accepted : 2018.09.13
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Purpose: Cardiotoxicity is a serious late complication of breast cancer treatment. Individual treatment risk of specific drugs has been investigated. However, studies on the evaluation of the composite risk of chemotherapeutic agents are limited. Methods: We retrospectively analyzed the medical records of breast cancer patients who received adjuvant treatment and had available serial echocardiography results. Patients were assigned to subgroups based on chemotherapy containing anthracyclines (A), anthracyclines and taxanes (A+T), and radiotherapy (RT). The development of cardiac disease and serial ejection fraction (EF) were reviewed. EF decline up to 10% from baseline was considered grade 1 cardiotoxicity and EF decline >20% or absolute value <50% was considered grade 2 cardiotoxicity. The most recent medical records and echocardiography results over 1 year of chemotherapy completion were also reviewed. Late cardiotoxicity was defined as a lack of recovery of EF decline or aggravated EF decline from baseline. Results: In total, 123 patients were evaluated. A small reduction in EF was observed after chemotherapy in both chemotherapy groups. There were no significant differences between groups A and A+T in EF decline following chemotherapy. We could not find any differences in composite risk between the chemotherapy groups and the RT group during follow-up. Late cardiotoxicity was seen in 15.45% of patients. During follow-up, three patients were diagnosed with dilated cardiomyopathy. Conclusion: There was no significant composite risk elevation following adjuvant treatment of breast cancer. However, late cardiotoxicity was considerable and further research in this direction is necessary.

Keywords

Acknowledgement

Supported by : Soonchunhyang University

References

  1. Wilbur J. Surveillance of the adult cancer survivor. Am Fam Physician 2015;91:29-36.
  2. Abdel-Qadir H, Austin PC, Lee DS, Amir E, Tu JV, Thavendiranathan P, et al. A Population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol 2017;2:88-93. https://doi.org/10.1001/jamacardio.2016.3841
  3. Park NJ, Chang Y, Bender C, Conley Y, Chlebowski RT, van Londen GJ, et al. Cardiovascular disease and mortality after breast cancer in postmenopausal women: results from the Women's Health Initiative. PLoS One 2017;12:e0184174. https://doi.org/10.1371/journal.pone.0184174
  4. Stava C, Weiss LT, Vassilopoulou-Sellin R. Health profiles of 814 very long-term breast cancer survivors. Clin Breast Cancer 2006;7:228-36. https://doi.org/10.3816/CBC.2006.n.034
  5. Zagar TM, Cardinale DM, Marks LB. Breast cancer therapy-associated cardiovascular disease. Nat Rev Clin Oncol 2016;13:172-84. https://doi.org/10.1038/nrclinonc.2015.171
  6. Guo S, Wong S. Cardiovascular toxicities from systemic breast cancer therapy. Front Oncol 2014;4:346.
  7. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606. https://doi.org/10.1136/bmj.b4606
  8. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ET. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol 2017;70:2552-65. https://doi.org/10.1016/j.jacc.2017.09.1095
  9. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al. vascular toxicities of cancer therapies: the old and the new: an evolving avenue. Circulation 2016;133:1272-89. https://doi.org/10.1161/CIRCULATIONAHA.115.018347
  10. Haque R, Shi J, Schottinger JE, Chung J, Avila C, Amundsen B, et al. Cardiovascular disease after aromatase inhibitor use. JAMA Oncol 2016;2:1590-7. https://doi.org/10.1001/jamaoncol.2016.0429
  11. Hatam N, Ahmadloo N, Ahmad Kia Daliri A, Bastani P, Askarian M. Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil). Arch Gynecol Obstet 2011;284:215-20. https://doi.org/10.1007/s00404-010-1609-8
  12. Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006;17:1205-12. https://doi.org/10.1093/annonc/mdl135
  13. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131:1981-8. https://doi.org/10.1161/CIRCULATIONAHA.114.013777
  14. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2017;35:893-911. https://doi.org/10.1200/JCO.2016.70.5400
  15. Domercant J, Polin N, Jahangir E. Cardio-oncology: a focused review of anthracycline-, human epidermal growth factor receptor 2 inhibitor-, and radiation-induced cardiotoxicity and management. Ochsner J 2016;16:250-6.
  16. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213-20. https://doi.org/10.1016/j.jacc.2009.03.095
  17. Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, et al. Survivorship, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017;15:1140-63. https://doi.org/10.6004/jnccn.2017.0146
  18. Cespedes Feliciano EM, Kwan ML, Kushi LH, Weltzien EK, Castillo AL, Caan BJ. Adiposity, post-diagnosis weight change, and risk of cardiovascular events among early-stage breast cancer survivors. Breast Cancer Res Treat 2017;162:549-57. https://doi.org/10.1007/s10549-017-4133-8
  19. Scott JM, Adams SC, Koelwyn GJ, Jones LW. Cardiovascular Late effects and exercise treatment in breast cancer: current evidence and future directions. Can J Cardiol 2016;32:881-90. https://doi.org/10.1016/j.cjca.2016.03.014
  20. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007;99:365-75. https://doi.org/10.1093/jnci/djk064
  21. Leung HW, Chan AL, Muo CH. Late cardiac morbidity of adjuvant radiotherapy for early breast cancer: a population-based study. J Cardiol 2016;67:567-71. https://doi.org/10.1016/j.jjcc.2015.07.009
  22. Lash TL, Thwin SS, Yood MU, Geiger AM, Bosco J, Quinn VP, et al. Comprehensive evaluation of the incidence of late effects in 5-year survivors of breast cancer. Breast Cancer Res Treat 2014;144:643-63. https://doi.org/10.1007/s10549-014-2885-y